Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical International has completed the construction of its pharmaceutical manufacturing facility in Yaroslavl, Russia.
Subscribe to our email newsletter
The €75m Yaroslavl facility will initially manufacture Cardiomagnyl, Actovegin and Calcium tablets to meet the Russian demand.
The 24,000m² facility will also manufacture 90 million sterile ampoules and more than 2 billion tablets per year.
Takeda president and chief executive officer Yasuchika Hasegawa said the completion of the project in Russia is part of strategic investment.
"The Yaroslavl facility will enable us to provide locally produced pharmaceutical products to patients and clinicians, as well as bringing significant benefits to the Yaroslavl and Russian economy," Hasegawa added.
Yaroslavl Region Governor Sergey Yastrebov said Takeda is one of the flagship companies in Yaroslavl’s pharmaceutical cluster and is the first international pharmaceutical company to invest in a new manufacturing facility in the region.
"This project is an excellent example of the benefits that international investment can bring to the Russian economy,"Yastrebov added.
The plant, which is expected to be operational by 2014, is anticipated to create 200 jobs initially.